Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

s' compounds to demonstrate safety and efficacy in clinical testing; Exelixis' ability to conduct and complete a phase 3 clinical trial for XL184 at the referenced time; Exelixis' ability to conduct clinical trials sufficient to achieve positive completion; Exelixis' ability to successfully advance and develop additional compounds; the therapeutic and commercial value of Exelixis' compounds; and Exelixis' ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under Exelixis' collaborative agreements. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended March 28, 2008, and other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... for the detection and quantification of partially hydrolyzed gluten in foods, has been ... Board adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... PARK, N.C., June 14, 2011 Bayer CropScience ( ... top innovative crop science companies in the areas of ... announced the release of a video featuring the organization,s ... award-winning program, Making Science Make Sense (MSMS) . ...
... PAREXEL International Corporation (NASDAQ: PRXL ... Wells Fargo Healthcare Conference in Boston, MA.  James Winschel, Sr. ... presentation on PAREXEL at 2:00 p.m. ET on Wednesday, June ... will be available through the "Investors" section of ...
... industry delivered solid top- and bottom-line growth in 2010, with ... a row. Yet funding for research and ... firms in the sector, which tend to be pre-commercial stage ... development. This has placed new pressure on the traditional biotech ...
Cached Biology Technology:Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 2Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 3Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 4Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center 5PAREXEL International to Present at Wells Fargo Healthcare Conference 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 3Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 4Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 5Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 6
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... on the growing mobile commerce market announces a revised version of ... week. The commercial will air on CNBC in New ... Angeles and San Francisco metro ... commercial focuses on Wocket,s ability to replace all the cards in ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... This release is available in French . ... in collaboration with Nova Scotia Agricultural College, have discovered what ... double the lifespan of Christmas trees in homes. The authors ... journal Trees . The researchers have identified a ...
... is not just a feature unique to humans and ... revealed that also brown trout have individual characters and ... Department of Zoology at the University of Gothenburg has ... from watercourses on the west coast of Sweden. ...
... of Change, literally took 100 years to write. The first ... It was repeated from 1956-1958 and a technical book was ... that first survey was approaching, ornithologists Mike Ward, Jeff Walk, ... to do it again and write a book, this time ...
Cached Biology News:Researchers discover a way to delay Christmas tree needle loss 2New book on 100 years of Illinois birds 2New book on 100 years of Illinois birds 3New book on 100 years of Illinois birds 4
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Cystatin F MAb (Clone 292103)...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
... an inhibitor of caspase-3/7 ... of inhibitor required to ... be determined empirically for ... inhibitor is sufficient to ...
Biology Products: